0001104659-22-081206.txt : 20220720 0001104659-22-081206.hdr.sgml : 20220720 20220720170415 ACCESSION NUMBER: 0001104659-22-081206 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220720 DATE AS OF CHANGE: 20220720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Innovatus Life Sciences Acquisition Corp. CENTRAL INDEX KEY: 0001846550 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 861553316 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-255075 FILM NUMBER: 221094823 BUSINESS ADDRESS: STREET 1: 777 THIRD AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2126984580 MAIL ADDRESS: STREET 1: 777 THIRD AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 RW 1 tm2221475d1_rw.htm RW

 

Innovatus Life Sciences Acquisition Corp.

777 Third Avenue, 25th Floor

New York, New York 10017

 

July 20, 2022

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

Attention:Maryse Mills-Apenteng

 

  Re: Innovatus Life Sciences Acquisition Corp.
   

Request for Withdrawal Pursuant to Rule 477 of Registration Statement on Form S-1

(File No. 333-255075)

 

Ladies and Gentlemen:

 

Pursuant to Rule 477 under the Securities Act of 1933, as amended, on behalf of Innovatus Life Sciences Acquisition Corp. (“we,” “us,” “our,” or the “Company”), we hereby submit this letter to notify the Securities and Exchange Commission (the “SEC”) of our withdrawal of our Registration Statement on Form S-1 (File No. 333-255075) (the “Registration Statement”) because the Company has elected to abandon the transactions subject thereto. The Registration Statement was not declared effective and no securities have been issued or sold under the Registration Statement.

 

If you have any questions or comments concerning this request, please call or contact our legal counsel, Joshua N. Englard, Esq. of Ellenoff Grossman & Schole LLP, at (212) 370-1300 or jenglard@egsllp.com.

 

  Sincerely,
   
  /s/ David Schiff 
  David Schiff
  Chief Executive Officer